probenecid has been researched along with 2019 Novel Coronavirus Disease in 3 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murray, J | 1 |
| Bergeron, HC | 1 |
| Jones, LP | 1 |
| Reener, ZB | 1 |
| Martin, DE | 3 |
| Sancilio, FD | 1 |
| Tripp, RA | 3 |
| Pandey, N | 1 |
| Chavda, P | 1 |
| Singh, G | 1 |
| Sutariya, R | 1 |
| Sancilio, F | 1 |
1 trial available for probenecid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19.
Topics: Adult; Antiviral Agents; COVID-19; Humans; Probenecid; SARS-CoV-2; Single-Blind Method | 2023 |
2 other studies available for probenecid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication.
Topics: Animals; COVID-19; Mice; Probenecid; Respiratory Syncytial Virus Infections; Respiratory Syncytial V | 2022 |
Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19.
Topics: Antiviral Agents; COVID-19; Drug Discovery; High-Throughput Screening Assays; Humans; Probenecid; Vi | 2023 |